Category Archives: Cancer and neoplasms

Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published in the July issue of eClinicalMedicine. Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues identified 1,496 tMDS/AML cases among […]

Brian A. Van Tine, MD, PhD, professor, Department of Medicine, Division of Oncology, Medical Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, discusses findings from the overall survival (OS) analysis of the phase 2 SPEARHEAD-1 trial (NCT04044768) in patients with advanced synovial sarcoma. The ongoing SPEARHEAD-1 trial is investigating the T-cell […]

The FDA previously approved the xT CDx assay for assessing microsatellite instability (MSI) status among patients with colorectal cancer (CRC) in May 2023. The FDA has granted breakthrough device designation to the HLA-LOH assay as a companion diagnostic test for use in patients with solid tumors, according to a press release from Tempus.1 The assay […]

Specialty

THURSDAY, Aug. 17, 2023 (HealthDay News) — Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published in the July issue of eClinicalMedicine. Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, […]

Ron Bentsur The FDA has granted an orphan drug designation to NXP800 for the treatment of patients with cholangiocarcinoma, according to an announcement from Nuvectis Pharma.1 “We are pleased to have received this designation from the FDA for NXP800, which emphasizes the need for new, innovative therapies for the treatment of cholangiocarcinoma, a deadly malignancy […]

Blood Cancer Does That MDS Diagnosis Need a Second Opinion? New research led by Mikkael Sekeres, MD, chief of Sylvester’s Division of Hematology, showed that blood cancers known as myelodysplastic syndromes/neoplasms (MDS) are commonly misdiagnosed, putting patients at risk for treatment mistakes and other potentially harmful consequences. Sekeres was corresponding author for the study, published […]

Data We conducted a descriptive study using nationally representative secondary cross-sectional data from the most recent round of the Nigerian Living Standard Survey (NLSS) conducted by Nigeria’s National Bureau of Statistics (NBS) between September 2018 and September 2019 [29]. The survey used a stratified multi-stage random sampling to sample 22,200 households with a mean household […]

Key Points Question  What is the prevalence and tumor spectrum of CDKN2A-related melanoma-astrocytoma syndrome? Findings  In this cohort study of 640 292 individuals in 2 population genomic databases, melanoma-astrocytoma syndrome prevalence ranged from 1 in 170 503 to 1 in 39 149, and patients had a diverse spectrum of neural and nonneural tumors. Multiple patients had clinical diagnoses […]